Biochemical and hematological side effects of clofazimine in leprosy patients

Pharmacological Research

Volumn 46, Issue 2, 2002, Pages 191-194

  Queiroz, Regina Helena Costa ^a   De Souza, Ana Maria ^a   Sampaio, Suely Vilela ^a   Melchior, Enzo ^a  

^a Fac Pharmaceutical Sci of S Paulo   (Brazil)

Author keywords

Clofazimine; Hematological and biochemical side effects; Leprosy patients

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMYLASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CLOFAZIMINE; CREATININE; DAPSONE; GAMMA GLUTAMYLTRANSFERASE; POTASSIUM; RIFAMPICIN; UREA;

ADULT; AGED; AMYLASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; CHEMICAL ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; ENTERITIS; EOSINOPHILIA; FEMALE; HEINZ BODY; HEMOLYTIC ANEMIA; HUMAN; HUMAN CELL; LEPROSY; MALE; METHEMOGLOBINEMIA; OSMOTIC FRAGILITY; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETICULOCYTE COUNT; SIDE EFFECT; SKIN DISCOLORATION; UREA BLOOD LEVEL;

EID: 0036417309     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-6618(02)00086-5     Document Type: Article

References (21)

1. Barry VC, Belton JG, Conalty ML. A new series of phenazines with high antituberculous activity. Nature 1957; 179: 1013-5.
2. Garrelts JC. Clofazimine: A review of its use in leprosy and Mycobacterium avium complex infection. Ann Pharmacother 1991; 25: 525-31.
3. Yawalker SJ, Vischer W. Lamprene (clofazimine) in leprosy. Lepr Rev 1979; 50: 135-44.
4. Mackey JP, Barnes J. Clofazimine in the treatment of discoid lupus erythematous. Br J Dermatol 1974; 91: 93-6.
5. Kaplan B, Trau H, Sofer E. Treatment of pyoderma gangrenosum with clofazimine. Int J Dermatol 1992; 31: 591-3.
6. Horsburgh CR Jr. Mycobacterium avium complex infection in acquired immunodeficiency syndrome. N Engl J Med 1991; 324: 1332-8.
7. Arbiser JL, Moschella SL. Clofazimine: A review of its medical uses and mechanisms of action. J Am Acad Dermatol 1995; 32: 241-7.
8. Banerjee DK, Ellard GA, Gammon PT, Waters MFR. Some observations on the pharmacology of clofazimine (B663). Am J Trop Med 1974; 23: 1110-9.
9. Levy L. Pharmacologic studies of clofazimine. Am J Trop Med Hyg 1974; 23: 1097-109.
10. Choudhri SH, Harris L, Butany JW, Keystone JS. Clofazimine-induced cardiotoxicity: A case report. Lepr Rev 1995; 66: 63-8.
11. Hastings RC, Jacobson RR, Trautman JR. Long-term clinical toxicity studies with clofazimine in leprosy. Int J Lep 1976; 44: 287-93.
12. Holdiness MR. Clinical pharmacokinetics of clofazimine. Clin Pharmacokinet 1989; 16: 74-85.
13. O'Connor R, O'Sullivan JF, O'Kennedy R. The pharmacology, metabolism, and chemistry of clofazimine. Drug Met Rev 1995; 27: 591-614.
14. Schaad-Lanyi Z, Dieterle W, Dubois JP, Theobald W, Vischer W. Pharmacokinetics of clofazime in healthy volunteers. Int J Lepr 1987; 55: 9-15.
15. Jopling WH. Complications of treatment of clofazimine. Lepr Rev 1976; 47: 1-3.
16. Desikan KV, Balakrishnan S. Tissue levels of clofazimine in a case of leprosy. Lepr Rev 1976; 47: 107-13.
17. Mansfield RE. Tissue concentrations of clofazimine in man. Am J Trop Med Hyg 1974; 23: 1116-9.
18. Reichlin S, Loveless MH, Kane E. Loeffler's syndrome following penicillin therapy. Ann Int Med 1953; 38: 113.
19. Fiegenberg DS, Weiss H, Krishman H. Migratory pneumonia with eosinophilia associated with sulphonamide administration. Arch Intern Med 1967; 120: 85.
20. Queiroz RHC, Melchior E Jr, Sousa AM, Gouveia E, Barbosa JC, Carvalho D. Pharmac Acta Helv 1997; 72: 209-13.
21. Kevin BP, Coleman JW, Kitteringham NR. Drug disposition and drug hypersensitivity. Biochem Pharmacol 1987; 36: 581-90.